These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35458385)

  • 1. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.
    Duan Q; Xia S; Jiao F; Wang Q; Wang R; Lu L; Jiang S; Xu W
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.
    Xia S; Yan L; Xu W; Agrawal AS; Algaissi A; Tseng CK; Wang Q; Du L; Tan W; Wilson IA; Jiang S; Yang B; Lu L
    Sci Adv; 2019 Apr; 5(4):eaav4580. PubMed ID: 30989115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.
    Lan Q; Wang C; Zhou J; Wang L; Jiao F; Zhang Y; Cai Y; Lu L; Xia S; Jiang S
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
    Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
    Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies.
    Su X; Huang Z; Xu W; Wang Q; Xing L; Lu L; Jiang S; Xia S
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses.
    Cai Y; Xu W; Tang J; Cao N; Lan Q; Lu L; Jiang S
    Cell Biosci; 2021 Jul; 11(1):128. PubMed ID: 34238357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.
    Xia S; Lan Q; Zhu Y; Wang C; Xu W; Li Y; Wang L; Jiao F; Zhou J; Hua C; Wang Q; Cai X; Wu Y; Gao J; Liu H; Sun G; Münch J; Kirchhoff F; Yuan Z; Xie Y; Sun F; Jiang S; Lu L
    Signal Transduct Target Ther; 2021 Jul; 6(1):288. PubMed ID: 34326308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
    Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
    mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    Lan Q; Wang L; Jiao F; Lu L; Xia S; Jiang S
    J Med Virol; 2023 Jan; 95(1):e28143. PubMed ID: 36098460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing fusion inhibitor peptide against SARS-CoV-2.
    Efaz FM; Islam S; Talukder SA; Akter S; Tashrif MZ; Ali MA; Sufian MA; Parves MR; Islam MJ; Halim MA
    J Comput Chem; 2021 Dec; 42(32):2283-2293. PubMed ID: 34591335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
    Jiao F; Andrianov AM; Wang L; Furs KV; Gonchar AV; Wang Q; Xu W; Lu L; Xia S; Tuzikov AV; Jiang S
    J Med Virol; 2023 Oct; 95(10):e29145. PubMed ID: 37804480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
    Xue S; Wang X; Wang L; Xu W; Xia S; Sun L; Wang S; Shen N; Yang Z; Huang B; Li S; Cao C; Calcul L; Sun X; Lu L; Cai J; Jiang S
    Cell Discov; 2022 Sep; 8(1):88. PubMed ID: 36075899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
    Lan Q; Chan JF; Xu W; Wang L; Jiao F; Zhang G; Pu J; Zhou J; Xia S; Lu L; Yuen KY; Jiang S; Wang Q
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein.
    Freidel MR; Vakhariya PA; Sardarni SK; Armen RS
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen.
    Wang X; Sun L; Liu Z; Xing L; Zhu Y; Xu W; Xia S; Lu L; Jiang S
    Emerg Microbes Infect; 2023 Dec; 12(2):2244084. PubMed ID: 37534910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
    Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
    mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
    Pasquero S; Gugliesi F; Griffante G; Dell'Oste V; Biolatti M; Albano C; Bajetto G; Delbue S; Signorini L; Dolci M; Landolfo S; De Andrea M
    Antiviral Res; 2022 Apr; 200():105278. PubMed ID: 35288208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
    Zhou J; Xu W; Liu Z; Wang C; Xia S; Lan Q; Cai Y; Su S; Pu J; Xing L; Xie Y; Lu L; Jiang S; Wang Q
    Acta Pharm Sin B; 2022 Apr; 12(4):1652-1661. PubMed ID: 34367893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.